Granules India working capital

Per cent unless marked ×
Tap a line for its trendLast 12Mto Jun 2026FY26Mar 2026FY25Mar 2025FY24Mar 2024FY23Mar 2023FY22 and earlierAlpha Plus
293.43×293.43×279.55×221.21×168.32×
FY22 and earlierEvery year the company has filed comes with Alpha Plus.
62.98×62.98×78.51×78.34×75.78×
136.11×136.11×156.05×138.29×123.73×
220.30×220.30×202.01×161.26×120.37×
3.36×3.20×4.03×5.48×5.93×
0.77×0.77×0.76×0.86×0.96×
1.33×1.33×1.73×1.08×1.43×
0.67×0.67×0.92×0.51×0.81×
Open the chart

From the company's filings with NSE and BSE (Ind-AS), consolidated. For information only, not investment advice.

GRANULES₹837.35

Granules India Ltd.

· Pharma & Health
₹ CrorePeersAUROPHARMAIPCALABAARTIDRUGSERISINDGNEMCUREJUBLPHARMACONCORDBIOMcap ₹20,750 Cr
ProfitabilityGrowthCreditLiquidityWorking CapitalYield AnalysisDuPont
Ratios — % unless marked ×
12 Months Ending
FY23
31/03/2023
FY24
31/03/2024
FY25
31/03/2025
FY26
31/03/2026
Last 12M
30/06/2026
Inventory Days (DIO)168.32221.21279.55293.43293.43
Receivable Days (DSO)75.7878.3478.5162.9862.98
Payable Days (DPO)123.73138.29156.05136.11136.11
Cash Conversion Cycle (days)120.37161.26202.01220.30220.30
Working Capital Turnover5.935.484.033.203.36
Asset Turnover0.960.860.760.770.77
Cash Conversion (CFO/Net Income)1.431.081.731.331.33
CFO/EBITDA0.810.510.920.670.67
No consensus estimates → no Est columns. Click any row to chart it.
« ‹ › »Latest: FY26 · ConsolidatedFA Financial Analysis · alphave
Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 95%.